QurAlis
Kevin Eggan is currently the CSO/SVP Head of Research and Early Development at BioMarin Pharmaceutical Inc. Kevin founded EnClear Therapies in 2018 and QurAlis in 2017. In 2013, they also founded Q-State Biosciences. Prior to these roles, they held various positions at Harvard University, starting as a Harvard Junior Fellow in 2003 and progressing to Professor. Kevin also served as a Principal Investigator at Harvard Stem Cell Institute. Additionally, they were a SAB member at Ipierian from 2009 to 2014.
Kevin Eggan obtained their Bachelor of Science (BS) degree in Microbiology and Immunology from the University of Illinois Urbana-Champaign from 1992 to 1996. Kevin then pursued further education at the Massachusetts Institute of Technology, where they completed their PhD in Biology from 1998 to 2003.
This person is not in any teams
This person is not in any offices
QurAlis
1 followers
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. They are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.